Virology Research Today is a free monthly online journal that collates and summarizes the latest research about Virology, including details on viruses, pathology, classification, definitions.

Volume 4 (2008), Issue 2 (February)

1. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
   Clin Gastroenterol Hepatol, 6(2): 234-41. [Abstract] [Full-text]
2. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
   Gastroenterology, 134(2): 405-15. [Abstract] [Full-text]
3. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics.
   J Community Health, 33(2): 69-77. [Abstract] [Full-text]
4. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects.
   J Infect Dis. [Abstract] [Full-text]
5. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.
   J Antimicrob Chemother, 61(3): 694-8. [Abstract] [Full-text]
6. Genotypic Resistance Profile and Clinical Progression of Treatment-Experienced HIV Type 1-Infected Patients with Virological Failure.
   AIDS Res Hum Retroviruses, 24(2): 149-54. [Abstract] [Full-text]
7. Burden of rotavirus-associated and non-rotavirus-associated diarrhea among nonhospitalized individuals in central Italy: a 1-year sentinel-based epidemiological and virological surveillance.
   Clin Infect Dis, 46(6): e51-5. [Abstract] [Full-text]
8. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
   Liver Int, 28(3): 407-11. [Abstract] [Full-text]
9. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
   Antimicrob Agents Chemother, 52(3): 1066-71. [Abstract] [Full-text]
10. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Aliment Pharmacol Ther, 27(7): 542-51. [Abstract] [Full-text]
11. Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research.
    J Acquir Immune Defic Syndr, 47: S5-9. [Abstract] [Full-text]
12. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    J Viral Hepat, 15(4): 300-4. [Abstract] [Full-text]
13. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    J Viral Hepat, 15(4): 293-9. [Abstract] [Full-text]

© 2005-2008 Virology Research Today. All Rights Reserved.